New drug combo shows promise in advanced cancers
NCT ID NCT04423029
First seen Mar 21, 2026 · Last updated Apr 29, 2026 · Updated 6 times
Summary
This early-phase study tested a new experimental drug called DF6002, given alone or with the immunotherapy nivolumab, in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Augusta University Georgia Cancer Center
Augusta, Georgia, 30912-0003, United States
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Clinica Universidad de Navarra - Madrid
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
Gustave Roussy
Villejuif, 94805, France
-
HealthPartners Cancer Center at Regions Hospital
Saint Paul, Minnesota, 55101, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hospital Universitari Vall d'Hebrón
Barcelona, 08035, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Huntsman Cancer Institute and Hospital
Salt Lake City, Utah, 84112, United States
-
Hôpital Saint-Louis
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Local Institution
Boston, Massachusetts, 02215, United States
-
Local Institution - 0022
Heidelberg, 3084, Australia
-
Local Institution - 0023
Box Hill, 3128, Australia
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
SCRI - HealthOne Denver
Denver, Colorado, 80218, United States
-
SCRI - Tennessee Oncology - Saint Thomas West Clinic
Nashville, Tennessee, 37205, United States
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
USOR - Virginia Cancer Specialists - Fairfax Office
Fairfax, Virginia, 22031, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.